Abstract

The emergence and spread of resistance in Enterobacteriaceae are complicating the treatment of serious nosocomial infections and threatening to create species resistant to all currently available agents. They are inhabitants of normal intestinal flora and are among the most common human pathogens, causing multiple infections . They are the source of community- and hospital-acquired infections. An observational study was conducted over a period of six months (July 2023 – December 2023) in the microbiology laboratory of Swami Ramanand Teerth Government Medical College , Ambajogai , Maharashtra . A total of 468 bacterial isolates of Enterobacteriaceae from clinical specimens were processed for antimicrobial susceptibility testing The rate of multidrug resistance and extended spectrum beta-lactamases production was 54.2% and 23.8% respectively. Of the total ESBL producers 92.4% were multidrug resistance. The rate of multidrug resistance and extended spectrum beta-lactamases production were higher in organisms isolated from clinical samples collected from inpatients. High rate of MDR and ESBL was seen in E. coli (54.7% & 21.4%), Klebsiella spp. (68% & 16.8%) and Citrobacter spp. (41.1% & 44.1%). The antimicrobial resistance rate was highest against ampicillin (80.3%) followed by cefixime (56.4%), ceftazidime (53.6%), ceftriaxone (53.0%), cotrimoxazole (51.2%), ciprofloxacin (45%) and ofloxacin (42.3%). Multidrug resistance is common among Enterobacteriaceae. These bacteria have high rate of resistance against commonly used groups of antibiotics like cephalosporins and quinolones. Continuous monitoring, surveillance of antimicrobial resistance, proper infection control and practices are important to combat with these issues.

Description